Theralase Technologies Inc. V.TLT

New Day - New Shout Out...

[Eoganacht]

Researchers in every corner of the globe seem aware of what's going on. Hopefully we hear more from urological oncologists soon.

Minimal Functionalization of Ruthenium Compounds with Enhanced Photoreactivity against Hard-to-Treat Cancer Cells and Resistant Bacteria

Gengela de Ftima Sousa Oliveira, Florencio Sousa Gouveia Jr., Alexandre Lopes Andrade, Mayron Alves de Vasconcelos, Edson Holanda Teixeira, Marcos V. Palmeira-Mello, Alzir A. Batista, Luiz Gonzaga de Frana Lopes, Idalina Maria Moreira de Carvalho, Eduardo Henrique Silva Sousa

 

Universidade Federal do Cear, Fortaleza, Brazil

Universidade Estadual do Cear, Itapipoca, Cear, Brazil

Universidade Federal de So Carlos, So Paulo, Brazil

ARTICLE July 23, 2024

 

Currently, a polypyridine ruthenium complex, TLD-1433, is in clinical trial phase II with promising treatment of nonmuscle invasive bladder cancer using PDT. Energy transfer is a key property of ruthenium complexes containing polypyridine ligands and anchored chromophores. Anthracene is an energy-donating chromophore that can transfer energy to a bipyridine ligand of the ruthenium complex upon light excitation. This energy transfer process can generate reactive oxygen species (ROS), such as singlet oxygen, which can damage DNA and proteins inside a tumor cell. Preclinical studies have shown that ruthenium complexes containing polypyridine ligands and anthracene exhibit antitumor activity in various tumor cell lines, including breast, prostate, and lung cancer opening broad opportunities for the development of new treatments. Beyond cancer therapy, photodynamic antimicrobial chemotherapy (PACT) has emerged with many opportunities considering the major threat of resistance that is faced globally. This issue has opened new avenues for systems first thought for cancer, and a series of properties have been investigated, including singlet oxygen photogeneration and DNA binding/cleavage, along with antimicrobial and cytotoxicity studies using cancer cell lines.

[DJDawg]

Great find. One thing that I hope TLT is ahead of is finding and validating an agent that can be activated by xrays. That is a huge thing to have since light can only penetrate mm in tissue. Eog, would that be correct? xray activation still appears to be an area where TLT is ahead?

[Eoganacht]

I think Theralase is ahead. But there could be any number of clinical trials going on I'm not aware of. A recent Theralase nr reported the destruction of NSCLC in mice using X-ray activated Rutherrin, so Theralase has a solution that works. But there may be room for improvement. XPDT overcomes the depth of penetration limitation of visible light but the difficulty is how effectively energy

[CancerSlayer]

Thanks Eoganacht...The Rutherrin-XPDT NSCLC preclinical results were very encouraging.  Do you happen to know if the Rutherrin was administered systemically as clinically intended?  The more closely preclinical studies emulate clinical conditions, the more meaningful the results & the higher the probability of clinical translation.   The ramifications of such positive results

[Eoganacht]

Thanks CancerSlayer. I'd guess the Rutherrin was delivered systemically but I don't really know. I'll ask.

[Dumbeldorfwhite]

Just stop with the spamming of useless information. Wow a study briefly cited their trial. 2 sentences in the article. We want actual real world results not hypotheticals

[wildbird1]

Eoganacht thanks for another very interesting find...(keep it coming). When TLT is properly funded, I would also like to see Dr.McFarland new SUPER PDCs COMPOUND being tested in a trial. https://theralase.com/theralase-researcher-discovers-super-potent-anti-cancer-drugs/ Question?????? How much $$$$ will a Big Pharma be willing to pay for a PDCs compound 10 billion times more potent than other

[Alamir1111]

How do you know that dr Mcfarland  will give rights to tlt.After all that is designed with radiation in mind not lasers